Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ocumension Pays $9.5 Million to Add Korean Rights for Two Products

publication date: Aug 20, 2020

Ocumension Therapeutics of Shanghai paid $9.5 million to add South Korea rights to its greater China in-licensing agreement with EyePoint Pharma for two ophthalmic products. In the US, Dexycu® is the first intraocular product approved to treat postoperative inflammation, and Yutiq® is a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Ocumension was established by 6 Dimensions Capital in 2018 to in-license ophthalmology products for China use. More details....

Stock Symbol: (NSDQ: EYPT)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.